top of page

Pre-clinical proof of concept and Clinical proof of concept (Phase I)

CAPTIVATE

at a glance

TARGET 

TIMELINE

COORDINATOR

FUNDER

FUNDING

Malaria (P. Falciparum)

01 November 2023 to 30 April 2028

European Vaccine Initiative

European Union

8.2 Mio Euro

SUMMARY

Correlates of Protective immunity-driven investigation of malaria vaccine combination strategies

CAPTIVATE will develop a new and improved vaccine targeting multiple developmental stages of P. falciparum, the most dangerous form of the malaria parasite. The consortium will optimise the efficacy of current pre-erythrocytic vaccines while evaluating the safety and immunogenicity of new blood-stage mRNA vaccine candidates, from pre-clinical testing to an early-stage clinical trial.
In parallel, the consortium will work on developing the next generation of highly efficacious malaria vaccine candidates using an advanced in-silico platform to analyse TCR- and single cell sequencing data in combination with artificial intelligence (AI) based predictions of novel malaria vaccine antigens.
The consortium will also establish a European facility for production of malaria sporozoites for research and clinical use

CAPTIVATE

PARTNERS

CAPTIVATE Consortium is comprised with experts in the fields of malaria modelling in primates, clinical vaccine testing, in-silico modelling of immune responses and innovative omics approaches:

-Deutsches Krebsforschungszentrum Heidelberg (Germany)
-European Vaccine Initiative (EVI) (Germany)
-Immunewatch (Belgium)
-Leiden University Medical Center (Netherlands)
-NEC OncoImmunity (Norway)
-Quantoom biosciences (Belgium)
-Stichting Biomedical Primate Research Center (Netherlands)
-University of New South Wales (Australia)

This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101081028.

bottom of page